Benjamin Machinas Beneski

CIK: 0002057918

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)6 (66.7%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ALLO

Allogene Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (9 total)

ALLO
Allogene Therapeutics, Inc.
Mar 31, 2026
Sale(S)
Direct
2.9K shares at avg. $2.50$7K
ALLO
Allogene Therapeutics, Inc.
Mar 16, 2026
Sale(S)
Direct
4.8K shares at avg. $2.47$12K
ALLO
Allogene Therapeutics, Inc.
Mar 2, 2026
Sale(S)
Direct
7.1K shares at avg. $2.60$19K
ALLO
Allogene Therapeutics, Inc.
Feb 2, 2026
Award(A)
Restricted Stock Unit
Direct
105.7K shares-
ALLO
Allogene Therapeutics, Inc.
Feb 2, 2026
Sale(S)
Direct
7.5K shares at avg. $1.73$13K
ALLO
Allogene Therapeutics, Inc.
Feb 2, 2026
Award(A)
Stock Option (Right to buy)
Direct
373.8K shares-
ALLO
Allogene Therapeutics, Inc.
Nov 17, 2025
Sale(S)
Direct
786 shares at avg. $1.22$958.92
ALLO
Allogene Therapeutics, Inc.
Mar 14, 2025
Sale(S)
Direct
5.5K shares at avg. $1.98$11K
ALLO
Allogene Therapeutics, Inc.
Mar 1, 2025
Award(A)
Direct
31.8K shares-

		Type	Shares	Price		Ownership
Mar 31, 2026	ALLO Allogene Therapeutics, Inc.	Sale(S)	2,867	$2.50	$7,168	Direct
Mar 16, 2026	ALLO Allogene Therapeutics, Inc.	Sale(S)	4,835	$2.47	$11,942	Direct
Mar 2, 2026	ALLO Allogene Therapeutics, Inc.	Sale(S)	7,132	$2.60	$18,543	Direct
Feb 2, 2026	ALLO Allogene Therapeutics, Inc.	Award(A) Restricted Stock Unit	105,720	-	-	Direct
Feb 2, 2026	ALLO Allogene Therapeutics, Inc.	Sale(S)	7,549	$1.73	$13,060	Direct
Feb 2, 2026	ALLO Allogene Therapeutics, Inc.	Award(A) Stock Option (Right to buy)	373,757	-	-	Direct
Nov 17, 2025	ALLO Allogene Therapeutics, Inc.	Sale(S)	786	$1.22	$959	Direct
Mar 14, 2025	ALLO Allogene Therapeutics, Inc.	Sale(S)	5,488	$1.98	$10,839	Direct
Mar 1, 2025	ALLO Allogene Therapeutics, Inc.	Award(A)	31,755	-	-	Direct

1-9 of 9 transactions

About Beneski Benjamin Machinas

Beneski Benjamin Machinas (SEC CIK 0002057918) files insider reports with the SEC as SVP, Chief Technical Officer of Allogene Therapeutics, Inc. (ALLO).

Signal8 holds 8 ownership filings by Beneski Benjamin Machinas (1 Form 3, 7 Form 4), filed between Mar 4, 2025 and Apr 2, 2026. Those filings report 9 transactions, from Mar 1, 2025 to Mar 31, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Beneski Benjamin Machinas's filings is in SOUTH SAN FRANCISCO, CA.

Recent filings by Beneski Benjamin Machinas

Mar 31, 2026: Open-market sale of ALLO shares (Form 4, code S).
Mar 16, 2026: Open-market sale of ALLO shares (Form 4, code S).
Mar 2, 2026: Open-market sale of ALLO shares (Form 4, code S).
Feb 2, 2026: Grant or award of ALLO derivative securities (Form 4, code A).
Feb 2, 2026: Open-market sale of ALLO shares (Form 4, code S).

Other insiders filing for Allogene Therapeutics, Inc. (ALLO)

Parker Geoffrey M., CHIEF FINANCIAL OFFICER
Douglas Earl Martin, SVP, General Counsel
Roberts Zachary, President and CEO
Kazam Joshua A, Director
MESSEMER DEBORAH M., Director
Mayo Stephen, Director

How to read Form 4 transaction codes